UK markets open in 4 hours 3 minutes

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
50.71-1.17 (-2.26%)
At close: 04:00PM EST
49.19 -1.52 (-3.00%)
After hours: 08:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 2.90B
Enterprise value 2.48B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)365.11
Price/book (mrq)6.76
Enterprise value/revenue 360.09
Enterprise value/EBITDA -17.83

Trading information

Stock price history

Beta (5Y monthly) 1.51
52-week change 315.14%
S&P500 52-week change 328.87%
52-week high 353.18
52-week low 322.11
50-day moving average 339.58
200-day moving average 332.95

Share statistics

Avg vol (3-month) 3810.04k
Avg vol (10-day) 31.6M
Shares outstanding 555.9M
Implied shares outstanding 657.19M
Float 851.87M
% held by insiders 10.34%
% held by institutions 1111.37%
Shares short (15 Feb 2024) 46.94M
Short ratio (15 Feb 2024) 410.13
Short % of float (15 Feb 2024) 414.60%
Short % of shares outstanding (15 Feb 2024) 412.42%
Shares short (prior month 12 Jan 2024) 46.22M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 311 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-850.33%

Management effectiveness

Return on assets (ttm)-21.70%
Return on equity (ttm)-37.45%

Income statement

Revenue (ttm)6.88M
Revenue per share (ttm)0.14
Quarterly revenue growth (yoy)156.10%
Gross profit (ttm)N/A
EBITDA -139.03M
Net income avi to common (ttm)-141.43M
Diluted EPS (ttm)-2.85
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)423.6M
Total cash per share (mrq)7.58
Total debt (mrq)2.54M
Total debt/equity (mrq)0.59%
Current ratio (mrq)13.87
Book value per share (mrq)7.68

Cash flow statement

Operating cash flow (ttm)-107.29M
Levered free cash flow (ttm)-46.7M